Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis

NCT01503021 is registered in ClinicalTrials.gov with Rockwell Medical Technologies, Inc. as lead sponsor.

NCT NCT01503021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01503021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Lead sponsor
Rockwell Medical Technologies, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
January 31, 2014
Enrollment
718 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, end stage renal disease